Does regression of electrocardiographic LVH during antihypertensive therapy reduce cardiovascular morbidity and mortality in persons with essential hypertension?
Regression of electrocardiographic LVH during antihypertensive therapy is an independent predictor of reduced cardiovascular morbidity and mortality.
Less-severe electrocardiographic LVH by Cornell product and Sokolow-Lyon voltage criteria during antihypertensive therapy is associated with lower likelihoods of CV morbidity and mortality, independent of blood pressure lowering and treatment modality in persons with essential hypertension. Antihypertensive therapy targeted at regression or prevention of electrocardiographic LVH may improve prognosis.
Peter M. Okin (Tue,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: